期刊文献+

口服2型糖尿病药物的研究进展 被引量:1

Current development of oral anti-type 2 diabetes mellitus agents
下载PDF
导出
摘要 文章简要介绍了2型糖尿病发病机制的最新研究结果。同时着重介绍了三大类口服2型糖尿病药物的研究现状。 The newly proposed pathogenesis of type 2 diabetes mellitus was reviewed. The three main kinds of oral antidiabetic agents were also reviewed in the paper.
出处 《安徽医药》 CAS 2006年第3期161-163,共3页 Anhui Medical and Pharmaceutical Journal
关键词 2型糖尿病 口服 发病机制 药物 type 2 diabetes mellitus oral pathogenesis agents
  • 相关文献

参考文献28

  • 1Jack L,Leahy.Pathogenesis of type 2 diabetes mellitus[J].Arch Med Res.2005,36(3):197-209.
  • 2Florez JC,Sjogren M.Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes[J].Diabetes,2004,53:3313-8.
  • 3Weiss R,Dziura J.Obesity and the metabolic syndrome in children and adolescents[J].N Engl J Med,2004,350:2362-74.
  • 4Turner RC,McCarthy ST,Holman RR,et al.Beta-cell function improved by supplementing basal insulin secretion in mild diabetes[J].Br Med J,1976,1:1252-4.
  • 5Weir GC.Non-insulin-dependent diabetes mellitus:interplay between B-cell inadequacy and insulin resistance[J].AmJMed,1982,73:461-4.
  • 6Evans AJ,Krentz AJ.Benefits and risks of transfer from oral Diabetes Care,1999,22:960-4 antidiabetic agents to insulin in type 2 diabetes.In:Krentz AJ editor.Drug treatment of type 2 diabetes[J].Auckland:Adis Books,2000:85-101.
  • 7杜伟奇,施秀芳,邱明艳,张文博.治疗糖尿病药物的研究进展[J].中国医院药学杂志,2005,25(1):70-72. 被引量:25
  • 8Rorsman P,Renstrom E.Insulin granule dynamics in pancreatic 574-9 beta cells[J].Diabetologica,2003,46:1029-45.
  • 9Rendell M.The role of sulfonylureas in the management of type effects 2 diabetes[J].Drugs,2004,64 (12):1339-58.
  • 10Yki-Jarvinen H.Combination therapies with insulin in type 2 diabetes[J].Diabetes Care,2001,24:758-67.

二级参考文献33

  • 1征革凡,王金平,张辉,胡泽溪,刘娟,肖建中,陈仕明,曹辉碧,李光伟,胡英华,潘孝仁.拜糖平治疗非胰岛素依赖型糖尿病的临床观察[J].中华内分泌代谢杂志,1995,11(3):163-164. 被引量:43
  • 2熊曼琪,朱章志.中医中药治疗非胰岛素依赖型糖尿病必须研究胰岛素抵抗[J].中医杂志,1995,36(1):47-49. 被引量:62
  • 3江蓓,张宝珠.拜糖平与糖尿病[J].中国实用内科杂志,1996,16(12):761-762. 被引量:4
  • 4Insucchi SE,Maggs DG,Spollett GR,et al.Efficacy and metabolic effects of troglitazone and metformin in NIDDM[J].Diabetes,1997,46(Suppl 1):34
  • 5Hotta N,K akuta H,K oh N,et al.The effects of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy[J].Diabetic Med,1993,10:355-358
  • 6Fertig B,Simmons D,Simonson D.Therapy for diabetes[A]//Ha-rris MEd,Bethesda Md.Diabetes in America[M].2nded.National Institutes of Health,NIH Publication No.95-1468,1995:519-534
  • 7Edelman SV,Henry RR.Insulin therapy for normalizing the glycosylated hemoglobin in type II diabetes:application,benefits and risks[J].Diabetes Reviews,1994,3:308-334
  • 8Scheen AJ,Lefebure PJ.Pathophysiology of Type 2 diabetes[A]//Kuhlmann J,PulsW.Handbook of experimental pharmacology:oral antidiabetics[M].Berlin:Springer Verlag,1995:7-42
  • 9Nolan JJ,Ludvik B,Beerdsen P,et al.Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone[J].N Eng J Med,1994,331(18):1188-1193
  • 10Kumar S,Boulton AJM,Beck-Nielsen H,et al.Troglitazone,an insulin action enhancer,improves metabolic control in NIDDM patients[J].Diabetologia,1996,39(6):701-709

共引文献31

同被引文献6

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部